2/2/2009

The FDA cleared Takeda Pharmaceutical's Kapidex delayed-release capsules, which treat gastroesophageal reflux disease. Kapidex is a new formulation of Prevacid, which made up 19% of the Japanese firm's revenue in the quarter that ended Sept. 30.

Related Summaries